Based on these results, we found that the existing immunosuppression created by the SPHK1-MTA3 axis could be reversed by anti-PD-1 mAb treatments, as demonstrated by the accumulation of tumor-infiltrating PD-1+CD8+ T cells. The gene discussed is SPHK1; the disease is neoplasm.